Compare MX & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MX | SPRO |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.1M | 156.3M |
| IPO Year | 2007 | 2017 |
| Metric | MX | SPRO |
|---|---|---|
| Price | $3.52 | $1.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.75 | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 2.0M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.06 | ★ 111.81 |
| EPS | N/A | N/A |
| Revenue | ★ $178,860,000.00 | $66,802,000.00 |
| Revenue This Year | $8.55 | N/A |
| Revenue Next Year | $6.37 | $300.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $2.18 | $1.08 |
| 52 Week High | $9.86 | $3.08 |
| Indicator | MX | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 37.42 | 18.94 |
| Support Level | $2.45 | N/A |
| Resistance Level | $4.76 | $2.44 |
| Average True Range (ATR) | 0.26 | 0.16 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 22.38 | 6.19 |
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The Company operates within a single operating segment, Power Solutions business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.